Our Blog & Resources

Analytical validation of HRD calculation performed with the OncoDEEP® Kit Comprehensive Genomic Panel

Introduction : HRD validation with OncoDEEP® Kit for ovarian cancer This poster highlights the results of a rigorous study conducted on 76 ovarian carcinoma samples from four Spanish hospitals. The OncoDEEP® kit stands out for...

Detection of Intraspecies Contamination as a Quality Control Tool in The OncoDEEP® Kit Comprehensive Genomic Panel

Introduction Next-Generation sequencing (NGS) emerged as a revolutionary technology in genomics research aiding precision medicine for almost two decades, but it has its challenges. One of which is the intraspecies contamination which could affect assay’s...

Dr. Ofer Elhanani I’m a staff scientist in Dr. Leeat Keren’s lab at the Weizmann Institute of Science in Israel. In our lab, we focus on research questions related to the interactions between tumor cells...

Scientific Review: latest discoveries in precision oncology

In a rapidly evolving medical landscape, staying updated with the latest breakthroughs is crucial. Our team of experts constantly monitors the field to bring you the most relevant and groundbreaking news. This month, we’ve handpicked...

Discover the latest version of our OncoKDM™ analysis software. In addition to delivering a comprehensive interpretation report, our platform now provides an even deeper analysis of QC data, empowering your laboratory with the precision necessary for accurate insights....

Comprehensive Genomic Profiling of Solid Tumor Patients for Broad Analysis in clinical diagnostics – A Comparative Analysis of OncoDEEP® Kit and Illumina TSO500

Comprehensive Pan-tumor Solution Comprehensive pan-tumor profiling of solid tumor is made possible with OncoDEEP® DNA and RNA Kit solutions. Designed for use with the powerful Next Generation Sequencing (NGS) technology, OncoDEEP® Kits can easily and...

DigiONE : A European digital research network for oncology

The rise of data standardisation in oncology with DigiONE Oncology is undergoing a major digital transformation. One of the most significant advances in this field is data standardisation, a process that DigiONE, the European digital...

March: 42-year-old male with a metastatic colorectal cancer

Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument.

Leading French and European comprehensive cancer center selects the OncoDEEP® Kit as the most complete solution with the highest number of relevant oncology biomarkers for use in its molecular laboratory.   Gosselies, Belgium and Paris,...

OncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing services

In the ever-evolving landscape of oncology clinical trials, the pursuit of precision has become synonymous with progress. In this era where tailored therapies hold the promise of improved patient outcomes, the foundation of reliable and...

February: 40-year-old male with a stage IV glioma cancer

Advancing personalized cancer treatment: Webinar Replay

Webinar replay available now: Unlocking precision medicine through expert NGS panel design Discover the Future of Personalized Cancer Treatment Thank you for your interest in our groundbreaking webinar on the latest advancements in cancer research...

Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer

Introduction: The integration of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (CX) marks a pivotal advancement in treating localized muscle-invasive bladder cancer (MIBC). Despite these efforts, approximately 45% of MIBC patients experience metastatic recurrence within...

Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinar

Unlocking precision medicine through expert NGS panel design Tuesday, February 13, 20244:00 PM CEST By Dr. Marcel Trautmann, Koenraad Eycken, Dr. James Flynn Join our webinar to discover revolutionary insights into personalised cancer treatment with...

Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccine

Medical research is taking a quantum leap forward with the PDC*neo+ project, promising a significant progress in the treatment of colorectal cancer. Thanks to OncoDNA’s unique expertise in neoantigen identification and circulating tumour DNA (ctDNA)...

January: 45-year-old male with an intrahepatic cholangiocarcinoma

We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance...

Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers

Overview: The technique of liquid biopsy represents a groundbreaking non-invasive method for tracking cancer progression and remission, particularly during treatment and follow-up phases. Despite its promise, the application of liquid biopsy in pediatric brain cancer...

OncoDNA laboratory has received the CAP accreditation

Gosselies, January 4th – The Certificate of Accreditation has been issued to the IntegraGen laboratory by The College of American Pathologists (CAP) for having successfully met the Laboratory Accreditation Program Standards. “The CAP accreditation is a critical step for OncoDNA, and we...

December: 52-year-old male with a stage IV gastric cancer

Case description: Gastric cancer is one of the leading causes of cancer-related mortality worldwide, with a 5-year survival rate ranging from 5% to 20% for advanced-stage cases (PMID: 30853093). We describe the case of a...

Ultra-sensitive detection of MRD through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer

Overview: The pivotal role of early detection of cancer recurrence and the precise monitoring of minimal residual disease (MRD) after surgery cannot be overstated, especially in the context of non-small cell lung cancer (NSCLC) where...

OncoDEEP Kits enable routine NGS workflow at the Institute of Pathology, Klinikum Region, Hanover, Germany

OncoDNA, a leading genomic and theranostic company specialising in precision medicine for cancer treatment, today has announced the implementation of OncoDEEP® Kit in clinical routine by the Institute of Pathology at the Klinikum Region Hannover...

OncoDNA supports the extension of AURORA study to identify molecular changes driving metastatic breast cancer

OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today has announced its support to the extension of the AURORA program, which aims to...

Join us in this video as Marcel Trautmann, Head of Molecular Diagnostics within the first German Department of Pathology and member of the German Network for Personalized Medicine (DNPM),  shares his firsthand experience with OncoDEEP®...

November: 68 year-old man with a Stage IV Prostate cancer

Case description: Prostate cancer is the fifth leading cause of cancer death in the world. When the cancer is localized, it is usually indolent, with a 5-year survival rate of nearly 100%. However, when the...

OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands

OncoKDM™ interpretation platform used in routine laboratory practice at ETZ (Elisabeth TweeSteden Hospital Pathologie Zuid-West Nederland) Tilburg, Netherlands The ETZ (Elisabeth-TweeSteden Hospital) is a leading hospital offering multiple clinical specialties including oncology and trauma across...

ctDNA’s promise in early detection of MRD and recurrence prediction for Head and Neck Squamous Cell Carcinoma

Two recent studies, led by the Institute Curie in collaboration with OncoDNA, have assessed the potential of circulating tumor DNA (ctDNA) as a biomarker for early detection of Molecular Residual Disease (MRD) and predicting recurrence...

October: 65 year-old woman with a Metastatic Breast Cancer with hormone receptor (HR)-positive

Case description: A 65 year-old woman was diagnosed with a metastatic breast cancer, hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Thanks to our OncoDEEP analysis, we notably detected a variant PIK3CA...

OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-house

OncoDNA launches the OncoSELECT Kit increasing laboratories capacity to provide liquid comprehensive genomic profiling in-house. Gosselies, Belgium, October 20th, 2023 – OncoDNA, a leading genomic and theranostic company specialising in precision medicine for cancer treatment,...

Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)

Comprehensive genomic profiling (CGP) and reliable molecular characterization of solid tumors using NGS technology has become a key tool to facilitate biomarker-matched therapy selection. With a broad spectrum of therapies already approved or in clinical...

C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across Europe

OncoDNA’s lab in France is the first in the EU to enable access to the C2inform test for clinical decision-making Gosselies — (October 19, 2023) — OncoDNA, a genomic and theranostic company specializing in precision...

Scientific Review: Latest Discoveries in Oncology

In a rapidly evolving medical landscape, staying updated with the latest breakthroughs is crucial. Our team of experts constantly monitors the field to bring you the most relevant and groundbreaking news. This month, we’ve handpicked...

Enhancing HRD Genomic Scar Result Interpretation: New Insights and Strategies

What is HRD Genomic Scar? The HRD Genomic Scar (GS) is essentially a collection of genetic changes or signatures that indicate a cell’s inability to repair DNA damage effectively using this specific DNA repair pathway....